Oracle Health Sciences InForm electronic data capture platform utilizes Proteus solution, enabling greater accuracy in measuring medication adherence during clinical trials.
Highly engaged patients that consistently take their prescribed medications as directed are the cornerstone of a successful clinical trial. Researchers have long struggled to effectively and efficiently validate adherence-relying on an arduous and often inaccurate combination of self-reporting and lab tests. To help health sciences organizations more effectively track and manage the use of medication during clinical trials, Oracle has introduced Oracle Health Sciences InForm Medication Adherence Insights Cloud Service.
This solution not only enables clinical trial sponsors to automatically capture precise and timely data about medication adherence, it can also help accelerate insight about drug efficacy and safety and speed clinical trials, which can, in turn, increase trial success rates.
News Facts
“Oracle Health Sciences InForm Medication Adherence Insights Cloud Service helps health sciences organizations effectively address two long-standing and complex challenges: measuring participant adherence to drug protocols and identifying the optimum dosing regimen for recommended use,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. “This groundbreaking solution-the direct result of a collaboration between Oracle and Proteus Digital Health-is a powerful example of how we can rapidly combine our industry-leading clinical trial data capture and management solutions with emerging technologies, such as digital pills, to help health sciences organizations transform the drug development and approval process.”
“The medication adherence option uniquely addresses the most critical information in a clinical trial: ‘Did the patients use their medicine properly?’ Combining this powerful new data with the technology, analysis, and capabilities of Oracle Health Sciences creates a game-changing opportunity for drug development,” said Markus Christen, head of global development, Proteus Digital Health.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.